{"id":340,"date":"2026-02-16T17:27:55","date_gmt":"2026-02-16T16:27:55","guid":{"rendered":"https:\/\/www.fprh.fr\/?p=340"},"modified":"2026-03-30T15:08:50","modified_gmt":"2026-03-30T13:08:50","slug":"resmetirom-acces-precoce-approuve-par-la-has-mash","status":"publish","type":"post","link":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/","title":{"rendered":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la  HAS (MASH)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Madrigal Pharmaceuticals via son exploitant en France, Clinigen Healthcare France, vient d\u2019obtenir l\u2019approbation de la Haute Autorit\u00e9 de Sant\u00e9 pour la mise \u00e0 disposition de REZDIFFRA (resmetirom) dans le cadre d\u2019un acc\u00e8s pr\u00e9coce post-AMM dans l\u2019indication suivante :<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab Rezdiffra est indiqu\u00e9 en association avec un r\u00e9gime alimentaire et de l\u2019exercice physique pour le traitement des adultes atteints de <strong>st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique sans cirrhose (MASH) avec fibrose h\u00e9patique avanc\u00e9e (fibrose de stade F3)<\/strong> \u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Il s\u2019agit d\u2019une autorisation conditionnelle de mise sur le march\u00e9 qui est accord\u00e9e lorsque le b\u00e9n\u00e9fice pour la sant\u00e9 publique de la disponibilit\u00e9 imm\u00e9diate l\u2019emporte sur le risque au fait que des donn\u00e9es suppl\u00e9mentaires soient encore n\u00e9cessaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>L\u2019indication retenue dans le cadre de cet acc\u00e8s pr\u00e9coce obtenue le 5 f\u00e9vrier 2026 pour la sp\u00e9cialit\u00e9 Rezdiffra est plus restrictive<\/strong> (patients atteints de MASH non cirrhotique avec fibrose h\u00e9patique avanc\u00e9e F3) que l\u2019autorisation conditionnelle de mise sur le march\u00e9 accord\u00e9e par la Commission Europ\u00e9enne en ao\u00fbt 2025 qui concerne les patients atteints de MASH non cirrhotique avec une fibrose h\u00e9patique mod\u00e9r\u00e9e \u00e0 avanc\u00e9e (stades de fibrose F2 \u00e0 F3).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cette autorisation d\u2019acc\u00e8s pr\u00e9coce est subordonn\u00e9e au respect d\u2019un protocole d\u2019utilisation th\u00e9rapeutique et de recueil des donn\u00e9es (PUT-RD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vous retrouverez les crit\u00e8res d\u2019\u00e9ligibilit\u00e9 et de non-\u00e9ligibilit\u00e9 sur le site de la HAS  : <a href=\"https:\/\/www.has-sante.fr\/jcms\/p_3859966\/fr\/rezdiffra-resmetirom-steatohepatite-mash\">Haute Autorit\u00e9 de Sant\u00e9 \u2013 REZDIFFRA (resmetirom) \u2013 St\u00e9atoh\u00e9patite MASH<\/a><\/p>\n\n\n\n<p class=\"has-text-align-left wp-block-paragraph\"><strong>La plateforme d\u2019acc\u00e8s pour inclure les patients et pour que les pharmaciens hospitaliers puissent commander ouvrira le lundi 23 f\u00e9vrier<\/strong>.<\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><strong>Plateforme de prescription du Resmetirom : <a href=\"https:\/\/www.clinigengroup.com\/direct\/fr\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.clinigengroup.com\/direct\/fr<\/a><\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><strong>LE RESMETIROM EN PRATIQUE <\/strong>(au 30 mars 2026)<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Indication<\/strong><\/td><td>En association avec un r\u00e9gime alimentaire et de l\u2019exercice physique pour le traitement des adultes atteints de st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique sans cirrhose (MASH) avec fibrose h\u00e9patique avanc\u00e9e (fibrose de stade F3)<\/td><\/tr><tr><td><strong>Contre-indication<\/strong><\/td><td>Inhibiteurs puissants du CYP2C8 (par exemple, le gemfibrozil)<\/td><\/tr><tr><td><strong>Pr\u00e9sentation<\/strong><\/td><td>Comprim\u00e9s \u00e0 60 mg, 80 mg, 100 mg<\/td><\/tr><tr><td><strong>Posologie<\/strong><\/td><td>80 mg 1\/j (si poids <100 kg) ; 100 mg 1\/j (si poids \u2265100 kg)<\/td><\/tr><tr><td><strong>Populations sp\u00e9cifiques<\/strong><\/td><td>-Statines\u00a0: rosuvastatine et simvastatine => max 20 mg\/j ; pravastatine et atorvastatine => max 40 mg\/j. -Inhibiteur mod\u00e9r\u00e9 du CYP2C8 (ex\u00a0: clopidogrel, d\u00e9f\u00e9rasirox, t\u00e9riflunomide) => r\u00e9duction dose (\u2265100 kg : 80 mg; <100 kg : 60 mg) -Insuffisance r\u00e9nale (clairance \u226515 ml\/min)\u00a0: pas d\u2019adaptation de posologie n\u00e9cessaire<\/td><\/tr><tr><td><strong>Oubli de prise<\/strong><\/td><td>Oubli d\u2019une dose : prendre la dose suivante \u00e0 l\u2019heure pr\u00e9vue, ne pas prendre une double dose pour compenser la dose oubli\u00e9e<\/td><\/tr><tr><td><strong>Effets secondaires<\/strong><\/td><td>-Diarrh\u00e9es (30%), naus\u00e9es (20%) ; c\u00e8de en 3-4 semaines -Prurit (10%) -\u00c9l\u00e9vations des enzymes h\u00e9patiques\u00a0(<1,5 x valeur initiale) : au cours du <sup>1er<\/sup> mois de traitement, retour \u00e0 la valeur initiale environ 8 semaines apr\u00e8s le d\u00e9but du traitement. -Fonction thyro\u00efdienne\u00a0: faible diminution des concentrations de FT4 (jusqu\u2019\u00e0 17% \u00e0 12 mois sous 100 mg); variations minimes de T3 ou TSH. Aucun r\u00e9sultat clinique n\u2019a \u00e9t\u00e9 associ\u00e9 aux diminutions de la FT4.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">(source : Pr Boursier, HGE, CHU Angers, JFHOD 2026)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Madrigal Pharmaceuticals via son exploitant en France, Clinigen Healthcare France, vient d\u2019obtenir l\u2019approbation de la Haute Autorit\u00e9 de Sant\u00e9 pour la mise \u00e0 disposition de REZDIFFRA (resmetirom) dans le cadre d\u2019un acc\u00e8s pr\u00e9coce post-AMM dans l\u2019indication suivante : \u00ab Rezdiffra est indiqu\u00e9 en association avec un r\u00e9gime alimentaire et de l\u2019exercice physique pour le traitement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,10],"tags":[17,18,21,20,26],"class_list":["post-340","post","type-post","status-publish","format-standard","hentry","category-actualite","category-masld-mash","tag-cancer","tag-foie","tag-mash","tag-masld","tag-traitement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites\" \/>\n<meta property=\"og:description\" content=\"Madrigal Pharmaceuticals via son exploitant en France, Clinigen Healthcare France, vient d\u2019obtenir l\u2019approbation de la Haute Autorit\u00e9 de Sant\u00e9 pour la mise \u00e0 disposition de REZDIFFRA (resmetirom) dans le cadre d\u2019un acc\u00e8s pr\u00e9coce post-AMM dans l\u2019indication suivante : \u00ab Rezdiffra est indiqu\u00e9 en association avec un r\u00e9gime alimentaire et de l\u2019exercice physique pour le traitement [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\" \/>\n<meta property=\"og:site_name\" content=\"FPRH - la federation des centres experts h\u00e9patites\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-16T16:27:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T13:08:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"341\" \/>\n\t<meta property=\"og:image:height\" content=\"172\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin9197\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin9197\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\"},\"author\":{\"name\":\"admin9197\",\"@id\":\"https:\/\/www.fprh.fr\/#\/schema\/person\/126da9c3dcc97fee69a4a1d857c202f4\"},\"headline\":\"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH)\",\"datePublished\":\"2026-02-16T16:27:55+00:00\",\"dateModified\":\"2026-03-30T13:08:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\/\/www.fprh.fr\/#organization\"},\"keywords\":[\"cancer\",\"foie\",\"MASH\",\"MASLD\",\"Traitement\"],\"articleSection\":[\"Actualit\u00e9\",\"MASLD\/MASH\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\",\"url\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\",\"name\":\"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites\",\"isPartOf\":{\"@id\":\"https:\/\/www.fprh.fr\/#website\"},\"datePublished\":\"2026-02-16T16:27:55+00:00\",\"dateModified\":\"2026-03-30T13:08:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.fprh.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fprh.fr\/#website\",\"url\":\"https:\/\/www.fprh.fr\/\",\"name\":\"FPRH - la federation des centre experts h\u00e9patites\",\"description\":\"Ensemble contre les Maladies du Foie !\",\"publisher\":{\"@id\":\"https:\/\/www.fprh.fr\/#organization\"},\"alternateName\":\"FPRH\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fprh.fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fprh.fr\/#organization\",\"name\":\"F\u00e9d\u00e9ration nationale des P\u00f4les de r\u00e9f\u00e9rence et R\u00e9seaux H\u00e9patites (FPRH)\",\"url\":\"https:\/\/www.fprh.fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.fprh.fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg\",\"contentUrl\":\"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg\",\"width\":341,\"height\":172,\"caption\":\"F\u00e9d\u00e9ration nationale des P\u00f4les de r\u00e9f\u00e9rence et R\u00e9seaux H\u00e9patites (FPRH)\"},\"image\":{\"@id\":\"https:\/\/www.fprh.fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/fprh-f\u00e9d\u00e9ration-nationale-des-p\u00f4les-de-r\u00e9f\u00e9rence-et-r\u00e9seaux-h\u00e9patites\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fprh.fr\/#\/schema\/person\/126da9c3dcc97fee69a4a1d857c202f4\",\"name\":\"admin9197\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.fprh.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1bbabf651aecd56a914482a24796c33c72e51240bce2f163e4aa184744001d45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1bbabf651aecd56a914482a24796c33c72e51240bce2f163e4aa184744001d45?s=96&d=mm&r=g\",\"caption\":\"admin9197\"},\"sameAs\":[\"http:\/\/byfvotf.cluster100.hosting.ovh.net\"],\"url\":\"https:\/\/www.fprh.fr\/index.php\/author\/admin9197\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/","og_locale":"fr_FR","og_type":"article","og_title":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites","og_description":"Madrigal Pharmaceuticals via son exploitant en France, Clinigen Healthcare France, vient d\u2019obtenir l\u2019approbation de la Haute Autorit\u00e9 de Sant\u00e9 pour la mise \u00e0 disposition de REZDIFFRA (resmetirom) dans le cadre d\u2019un acc\u00e8s pr\u00e9coce post-AMM dans l\u2019indication suivante : \u00ab Rezdiffra est indiqu\u00e9 en association avec un r\u00e9gime alimentaire et de l\u2019exercice physique pour le traitement [&hellip;]","og_url":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/","og_site_name":"FPRH - la federation des centres experts h\u00e9patites","article_published_time":"2026-02-16T16:27:55+00:00","article_modified_time":"2026-03-30T13:08:50+00:00","og_image":[{"width":341,"height":172,"url":"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg","type":"image\/jpeg"}],"author":"admin9197","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin9197","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#article","isPartOf":{"@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/"},"author":{"name":"admin9197","@id":"https:\/\/www.fprh.fr\/#\/schema\/person\/126da9c3dcc97fee69a4a1d857c202f4"},"headline":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH)","datePublished":"2026-02-16T16:27:55+00:00","dateModified":"2026-03-30T13:08:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/"},"wordCount":555,"publisher":{"@id":"https:\/\/www.fprh.fr\/#organization"},"keywords":["cancer","foie","MASH","MASLD","Traitement"],"articleSection":["Actualit\u00e9","MASLD\/MASH"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/","url":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/","name":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH) - FPRH - la federation des centres experts h\u00e9patites","isPartOf":{"@id":"https:\/\/www.fprh.fr\/#website"},"datePublished":"2026-02-16T16:27:55+00:00","dateModified":"2026-03-30T13:08:50+00:00","breadcrumb":{"@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.fprh.fr\/index.php\/2026\/02\/16\/resmetirom-acces-precoce-approuve-par-la-has-mash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.fprh.fr\/"},{"@type":"ListItem","position":2,"name":"Resmetirom acc\u00e8s pr\u00e9coce approuv\u00e9 par la HAS (MASH)"}]},{"@type":"WebSite","@id":"https:\/\/www.fprh.fr\/#website","url":"https:\/\/www.fprh.fr\/","name":"FPRH - la federation des centre experts h\u00e9patites","description":"Ensemble contre les Maladies du Foie !","publisher":{"@id":"https:\/\/www.fprh.fr\/#organization"},"alternateName":"FPRH","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fprh.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.fprh.fr\/#organization","name":"F\u00e9d\u00e9ration nationale des P\u00f4les de r\u00e9f\u00e9rence et R\u00e9seaux H\u00e9patites (FPRH)","url":"https:\/\/www.fprh.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.fprh.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg","contentUrl":"https:\/\/www.fprh.fr\/wp-content\/uploads\/2025\/05\/logo_FPRH_2025.jpg","width":341,"height":172,"caption":"F\u00e9d\u00e9ration nationale des P\u00f4les de r\u00e9f\u00e9rence et R\u00e9seaux H\u00e9patites (FPRH)"},"image":{"@id":"https:\/\/www.fprh.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/fprh-f\u00e9d\u00e9ration-nationale-des-p\u00f4les-de-r\u00e9f\u00e9rence-et-r\u00e9seaux-h\u00e9patites\/"]},{"@type":"Person","@id":"https:\/\/www.fprh.fr\/#\/schema\/person\/126da9c3dcc97fee69a4a1d857c202f4","name":"admin9197","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.fprh.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1bbabf651aecd56a914482a24796c33c72e51240bce2f163e4aa184744001d45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1bbabf651aecd56a914482a24796c33c72e51240bce2f163e4aa184744001d45?s=96&d=mm&r=g","caption":"admin9197"},"sameAs":["http:\/\/byfvotf.cluster100.hosting.ovh.net"],"url":"https:\/\/www.fprh.fr\/index.php\/author\/admin9197\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/posts\/340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/comments?post=340"}],"version-history":[{"count":8,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/posts\/340\/revisions"}],"predecessor-version":[{"id":357,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/posts\/340\/revisions\/357"}],"wp:attachment":[{"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/media?parent=340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/categories?post=340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fprh.fr\/index.php\/wp-json\/wp\/v2\/tags?post=340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}